Advertisement
Advertisement
November 1, 2016
Neuravi Secures €15 Million to Support Expansion of Stroke Treatment Portfolio
November 2, 2016—Neuravi announced €15 million in growth debt financing that will allow the company to invest in the expansion of its stroke treatment portfolio.
The Ireland-based company intends to build its commercial presence in the United States and further invest in research and development for its product pipeline for acute ischemic stroke treatment that will be commercialized globally in the coming years.
Neuravi’s EmboTrap and EmboTrap II are available in Europe to treat patients with acute ischemic stroke. The EmboTrap was commercialized in Europe in 2015. In September 2016, the company announced the European CE Mark approval and launch of the EmboTrap II revascularization device, which included enhancements to the EmboTrap stent retriever platform.
In the United States, the EmboTrap is currently available for investigational use only in the ARISE II clinical trial. The trial is assessing safety and effectiveness of the device in the United States and Europe. Data from the trial will support a US Food and Drug Administration submission for approval.
The financing was provided by Luxembourg-based IPF Partners, an alternative financing provider focused on the health care sector.
Advertisement
Advertisement
